Scholarlink

<p>Quantitative systems pharmacology (QSP) models of cancer immunity provide mechanistic insights into cellular dynamics and drug effects that are difficult to study clinically. However, their inability to predict patient survival mechanistically limits their utility in anti-cancer drug development. To overcome this, we link virtual patients from a QSP model to real clinical trial patients. Using data from atezolizumab trials in non-small cell lung cancer, we show that tumor-based linkage effectively captures survival outcomes. By treating linked survival and censoring as weak supervision labels, we trained survival models using only QSP model covariates, without clinical covariates. Our approach also predicts survival for treatments not included in training data. Specifically, we accurately estimated survival hazard ratios (HR) for chemotherapy monotherapy and atezolizumab plus chemotherapy combination. The predicted HR of 0.70 (95% prediction interval [PI] 0.55–0.86) closely matches the observed HR of 0.79 (95% PI 0.64–0.98) from the IMpower130 trial.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Predicting survival in prospective clinical trials using weakly-supervised QSP

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月14日

查看全文
  • Matthew West,
  • Kenta Yoshida,
  • Jiajie Yu,
  • Vincent Lemaire

摘要

Quantitative systems pharmacology (QSP) models of cancer immunity provide mechanistic insights into cellular dynamics and drug effects that are difficult to study clinically. However, their inability to predict patient survival mechanistically limits their utility in anti-cancer drug development. To overcome this, we link virtual patients from a QSP model to real clinical trial patients. Using data from atezolizumab trials in non-small cell lung cancer, we show that tumor-based linkage effectively captures survival outcomes. By treating linked survival and censoring as weak supervision labels, we trained survival models using only QSP model covariates, without clinical covariates. Our approach also predicts survival for treatments not included in training data. Specifically, we accurately estimated survival hazard ratios (HR) for chemotherapy monotherapy and atezolizumab plus chemotherapy combination. The predicted HR of 0.70 (95% prediction interval [PI] 0.55–0.86) closely matches the observed HR of 0.79 (95% PI 0.64–0.98) from the IMpower130 trial.